MannKind Corporation has announced yesterday that it has initiated enrollment of patients in phase 3 safety trial of inhaled Technosphere® Insulin (TI) in the United States.
The company, that was founded by the legendary innovator of medgadgets Alfred Mann, describes its dry inhaled insulin:
The MannKind inhaled insulin delivery system consists of a proprietary dry powder Technosphere® formulation of insulin that is inhaled into the deep lung using MannKind Corporation’s proprietary MedTone® inhaler, which utilizes single-use, disposable, plastic cartridges containing Technosphere® Insulin powder.
The inhaler is light, easy to use, and fits in the palm of the patient’s hand, which is believed to facilitate patient compliance.
Technosphere Insulin is stable for at least 18 months under refrigerated conditions and for at least two months at room temperature, which is equivalent to or surpasses commercially available insulin products.
The combination of Technosphere® Insulin’s unique performance characteristics including the rapid transfer of the insulin into the blood and the significantly higher bioavailability, along with the convenience and ease of use of the MedTone® inhaler, may have the potential to change the way diabetes is treated.
(hat tip: Medicine and Man)
